[Angioprotective activity of mexicor in atherosclerosis obliterans of the lower limbs].
The authors have studied mexicor's efficacy in a comprehensive treatment of 25 patients suffering from atherosclerosis obliterans of the lower extremities with grade II-III ischaemia. The state of the vascular bed and the degree of arteries' narrowing were assessed by means of colour duplex scanning of the lower limb arteries using the unit Vivid 7 manufactured by the Company <<General Electrics>>. The angiographic examination of the vessels of the lower extremities was carriedout on the angiographic complex manufactured by the Company Siemens Multistar T.O.P. The volume of the filling of the vessels of the lower limbs was evaluated by the parameters of the rheogram registered on the rheograph 4RG-1A. It was determined that the inclusion of mexicor (5-6% ml intravenously dropwise, 300 mg/day) into the standard therapeutic regimen significantly increased the efficacy of the conventional management of atherosclerosis obliterans of the arteries of the lower limbs, accelerating regression of the main clinical symptoms of ischaemia, increasing the distance of pain-free walking, correcting dyslipidaemia, and excreting an antioxidant action.
Inchina
V I
VI
Smirnov
L D
LD
Romanov
M D
MD
Kokoreva
E V
EV
Morozov
M Iu
MIu
D000792:Angiography; D001162:Arteriosclerosis Obliterans / Q000000981:diagnostic imaging / Q000188:drug therapy*; D005500:Follow-Up Studies; D006801:Humans; D007262:Infusions, Intravenous; D007866:Leg / Q000098:blood supply*; D008297:Male; D008875:Middle Aged; D010992:Plethysmography, Impedance; D011725:Pyridines / Q000008:administration & dosage*; D016896:Treatment Outcome; D018616:Ultrasonography, Doppler, Duplex
D011725:Pyridines; C517040:ethylmethylhydroxypyridine succinate